A novel cytokine interleukin (IL)-23 bears a structural and functional resemblance to IL-12. A recombinant adenovirus expressing IL-23N220L (recombinant replication-defective adenovirus (rAd)/IL-23N220L) that selectively secrets IL-23 was constructed and compared with rAd/IL-12N220L in terms of immunological and antitumor effects. In a prophylactic setting, vaccination with rAd/ ovalbumin (OVA) and rAd/IL-23N220L enhanced OVA-specific CD8 þ T-cell responses that were closely associated with complete protection against the subsequent challenge of OVA-expressing E.G7 thymoma. However, in a therapeutic setting, the intratumoral injection of rAd/IL-23N220L showed only marginal antitumor activity against several established tumors such as E.G7, CT26 and B16F10. Interestingly, whereas IL-23 still induced tumor-specific CD8 þ T-cell responses, it could not activate natural killer (NK) cells in vitro and in vivo. In addition, the adoptive transfer of activated NK cells partially restored the therapeutic antitumor effect of IL-23, indicating that NK cells are one of the crucial factors responsible for the regression of established tumors. Taken together, we demonstrated that adenovirus-mediated gene transfer of IL-23 induces a potent prophylactic, but not a therapeutic, antitumor effect.
Introduction
Prophylactic and therapeutic cancer vaccines are two main applications of immunology to oncology. Prophylactic vaccines implement immunological maneuvers before tumor onset to induce an immune response followed by protection for the host from carcinogenesis and tumor progression, whereas therapeutic vaccine consists of immunological interventions to eliminate existing tumor cells. Various studies have stressed the differences between prophylactic and therapeutic vaccines, particularly, in terms of time for the induction of the immune reaction, status of the immune system, foremost effector mechanisms and required duration of the induced immune response. 1 Therefore, the therapeutic strategy should be different from the preventive strategy in developing cancer vaccines.
Recent advancements in cancer vaccines or immunotherapy have focused on the cytokine-mediated antitumor effect, as some cytokines of themselves or as adjuvants can regulate the cross talk between innate and adaptive immunity, leading to the promotion of antitumor immunity. 2 Among the many cytokines evaluated as antitumor agents, interleukin (IL)-12 has been shown to have a highly potent antitumor activity in several comparative studies. [3] [4] [5] IL-23, as a novel IL-12 family cytokine, was recently identified and is composed of the p19 subunit and the p40 subunit of IL-12. 6 The IL-23 receptor complex (IL-23R), composed of the IL-12Rb1 and the IL-23R subunit, is expressed or upregulated in T and natural killer (NK) cells, as well as in macrophage and dendritic cells (DCs). 7 IL-23 is secreted from activated DC, and enhances proliferation of memory T cells and production of interferon (IFN)-g from activated T cells. 6 In addition, IL-23 activates a unique T-cell subset to produce IL-17, leading to its dominant role in autoimmune inflammation. 8 Recently, mouse colon carcinoma cells transduced with a p40-p19 IL-23 fusion protein grew into palpable tumors, but spontaneously regressed, indicating the antitumor effect of IL-23. 9 On the other hand, it has been reported that the expression of IL-23 was increased in a human tumor and the growth of the transplanted tumor was restricted in hosts depleted for IL-23 or IL-23R, indicating the role of IL-23 in promoting tumor incidence and growth. 10 Therefore, it is of interest to further explore the antitumor effects and action mechanisms of IL-23 for providing new insight in developing cancer vaccine and immunotherapy.
The systemic delivery of recombinant cytokine proteins showed antitumor effects, but often resulted in severe side effects and toxicities. 11 Instead, cytokine gene therapy could achieve a temporary high local concentration of cytokines within a tumor with a lowered risk of systemic toxicity. 11 In particular, adenoviral-based cytokine gene therapy has many advantages over other forms of cytokine delivery, as adenoviral vectors allow local and transient high levels of transgene expression. 12 IL-23 gene-based immunotherapy requires the delivery of two genes, p19 and p40, due to their heterodimeric structure, 6 which leads to the production of p40 in excess of IL-23. 13 The p40 subunit might block the binding of IL-23 to its receptor and inhibit IL-23-mediated biological activity. We previously demonstrated that the N-glycosylation mutant at Asn220 of the mouse p40 subunit, IL-23N220L, selectively decreased the secretion of p40, and that IL-23N220L exhibited a stronger Th1-prone immune response than did native IL-23 in the DNA vaccine model. 13, 14 Therefore, IL-23N220L is expected to be more useful than IL-23 in studying the antitumor effects of IL-23 gene-mediated immunotherapy.
In this study, we compared the immunological and antitumor effects of IL-23 with those of IL-12 using recombinant replication-defective adenovirus (rAd) encoding IL-23N220L (rAd/IL-23N220L) and IL-12N220L (rAd/IL-12N220L) in both prophylactic and therapeutic settings. We were especially interested in determining the stimulatory effect of IL-23 on NK and tumor-specific CD8 þ T cells due to the irrefutable role of these cells in cancer immunity. Our results will be valuable in providing information on rational design of cytokine gene-based immunoprophylactic and immunotherapeutic strategies against cancer.
Materials and methods

Mice and tumor cell lines
Six-week-old female BALB/c and C57BL/6 mice were purchased from Charles River Breeding Laboratories (Shizuoka, Japan), whereas C57BL/6J-Lyst bg-J (beige mutation) mice were obtained from the Jackson Laboratory (Bar Harbor, ME). All the mice were housed in a pathogen-free environment in an internally approved vivarium at the Institute.
CT26, B16F10, E.G7 and YAC-1 cells were purchased from American Type Culture Collection (Manassas, VA). CT26, B16F10 and E.G7 cell cultures were maintained in Dulbecco's modified Eagle's medium (BioWhittaker, Valkersville, MD) and YAC-1 cells in RPMI 1640 (BioWhittaker), supplemented with 10% fetal bovine serum (Hyclone, Logan, UT) and 1 g each of penicillin/ streptomycin (Life Technologies Inc., Grand Island, NY) per 100 ml.
Construction of recombinant replication-defective adenoviruses
Recombinant replication-defective adenoviruses were generated according to the AdEasy Vector System (QBiogene, Carlsbad, CA), and rAd/IL-12N220L was constructed as described earlier. 15 Briefly, the cDNA of murine IL-12N220L, 14 IL-23, IL-23N220L 13 and chicken ovalbumin (OVA) 16 were subcloned into the adenoviral shuttle vector, pShuttleCMV. After recombination with the adenoviral backbone vector, pAdEasy in Escherichia coli BJ5183, the recombinant adenoviruses were generated and expanded in 293 cells. After transient infection of each recombinant adenovirus into COS7 cells, the expression of IL-12 and IL-23 were measured by IL-12p70 (R&D System, Minneapolis, MN) and IL-23 (eBioscience, San Diego, CA) ELISA kits, respectively.
Experimental protocol in prophylactic and therapeutic settings For the tumor protection experiment, the C57BL/6 mice were intramuscularly injected with rAd/OVA having either rAd/IL-23N220L or rAd/IL-12N220L, each at a dose of 5 Â 10 6 plaque-forming unit (PFU). At 5 weeks, each mouse was subcutaneously challenged with 5 Â 10 5 E.G7 tumor cells in 100 ml of endotoxin-free phosphatebuffered saline (PBS) in the right hind flank. For the tumor treatment experiment, 5 Â 10 5 E.G7, B16F10 and CT26 cells in 100 ml PBS were subcutaneously injected into the right hind flank of C57BL/6 and BALB/c syngeneic mice, respectively. After palpable tumor formation (a mean diameter of 7 mm), the mice were intratumorally injected with 2 Â 10 8 PFU of each rAd three times every second day. For the adoptive transfer experiment, the mice bearing CT26 and B16F10 tumors were intravenously injected with 2 Â 10 6 NK cells activated by polyinosinic:polycytidylic acid (poly I:C, Sigma-Aldrich, St Louis, MO) on day 1 after rAd injection. Tumor size was measured at least twice a week with a digital caliper for the two-dimensional longest axis (L in mm) and shortest axis (W in mm), and the tumor volume was calculated using the following formula:
)/2. Animals with tumors that exceeded 15 mm in two perpendicular diameters or 20 mm in one diameter were killed for ethical reasons according to institutional guidelines.
Measurement of CD8
þ T-cell activity ELISPOT assay was performed as described previously. 15 Briefly, after harvesting splenocytes from the mice on indicated days, the cells were co-incubated with OVA 257-264 peptide (SIINFEKL) or mitomycin C-treated tumor cells on an IFN-g capture antibody (BD Pharmingen, San Diego, CA)-coated 96-well ELISPOT plate (Millipore, Bedford, MA) for 24 h. After subsequent incubation with biotinylated rat anti-mouse IFN-g antibody (BD Pharmingen), the number of spots was counted using the AID ELISPOT Reader System (Autoimmun Diagnostika, Strassberg, Germany). The average number of IFN-g secreting cells was shown per 1 Â 10 6 splenocytes. After the harvested splenocytes were stimulated with mitomycin C-treated tumor cells in the presence of 5 mg ml À1 of Brefeldin A (Sigma-Aldrich) for 6 h, cell surface CD8 marker staining, intracellular IFN-g staining and flow cytometry analysis were performed as described previously. 17 Measurement of NK cell activity NK cells were enriched by incubating splenocytes with anti-NK (DX5) microbeads (Miltenyi Bitotech, Auburn, CA) as previously described. 18 NK cell enrichment was confirmed by flow cytometric analysis using CD3 and DX5 markers (BD PharMingen). The enriched CD3 À DX5 þ NK cells from naive mice were stimulated with the culture supernatants derived from rAd/Mock, rAd/IL-23N220L and rAd/IL-12N220L, and recombinant IL-23 and IL-12 (R&D System) for 48 h. In a therapeutic setting, the NK cells were isolated from CT26 tumor-bearing mice at day 2 after intratumoral injection of each recombinant adenovirus, and at day 1 after intraperitoneal treatment with 150 mg of poly I:C. The cytotoxicity of NK cells was determined by incubation at the indicated effector to target ratio with 1 Â 10
Cr-labeled CT26 and NK-sensitive YAC-1 cells. After incubation for 5 h, the supernatants were harvested and counted with a gamma counter (Wallac, Turku, Finland). The maximum or spontaneous release of 51 Cr was determined from the cells treated with either 2% Triton X-100 or medium, respectively. The percentage of specific lysis was calculated as ((experimental releaseÀsponta-neous release)/(maximum releaseÀspontaneous release)) Â 100.
Statistical analysis
All data expressed as means ± s.e.m. are representative of at least two different experiments. The data presenting the differences between the groups were assessed using a Student's t-test, and the P-values were calculated using the log-rank test for comparison. Po0.05 indicated that the value of the test sample was significantly different from that of the relevant controls.
Results
Co-delivery of rAd/IL-23N220L significantly enhances antigen-specific CD8
þ T-cell responses, followed by complete protection against tumor challenge To investigate the effects of IL-23 gene transfer on antitumor activity and its immune correlates, a rAd expressing IL-23N220L, N-glycosylation mutant at Asn 220 of the mouse p40 subunit that selectively decreases the secretion of p40, 13 was constructed. Its correct expression was verified by enzyme-linked immunosorbent assay after transient infection into COS7 cells (data not shown). In a prophylactic setting, the rAd expressing OVA as a surrogate tumor antigen (rAd/OVA) was vaccinated with rAd/IL-23N220L, and OVA-specific CD8 þ T-cell response was determined by IFN-g ELISPOT assay at 4 weeks post-immunization (wpi). Mice co-injected with rAd/IL-23N220L showed a higher frequency of IFN-gproducing CD8
þ T cells than those with rAd/OVA alone, which is statistically meaningful (Figure 1a ). At 5 wpi, all vaccinated mice were challenged with E.G7 tumor cells expressing OVA. As expected, rAd/OVA-immunized mice showed a retardation of tumor growth as compared to rAd/Mock-immunized mice, leading to a survival rate of 25% (Figures 1b and c) . The co-injection of rAd/IL-23N220L with rAd/OVA further suppressed tumor progression and resulted in the survival of all immunized mice (Figures 1b and c) . These CD8 þ T-cell response and protective antitumor effects induced by IL-23 were similar to those induced by IL-12 when rAd/IL-12N220L was coinjected with rAd/OVA at the same dose of rAd/IL-23N220L (data not shown). These results indicate that adenovirus-mediated gene transfer of IL-23 with tumor antigen has a strong antitumor activity in a prophylactic setting, which is comparable to IL-12.
IL-23 exhibits a little antitumor effect in a therapeutic setting The elimination of preexisting tumor cells in the cancerbearing host has been suggested as the major goal of tumor immunotherapy. Thus, we investigated the therapeutic potential of rAd/IL-23N220L using three different murine tumor models (E.G7, B16F10 and CT26). Mice bearing the palpable tumors were intratumorally injected three times with rAd/IL-23N220L. As positive and negative controls, rAd/IL-12N220L and rAd/Mock were used, respectively. rAd/IL-12N220L treatment elicited a potent effect on tumor regression in all of the tumor models (Figure 2 ), which is in agreement with our previous report. 15 However, the rAd/IL-23N220L treatment showed only a marginal antitumor effect, which was statistically insignificant as compared to the rAd/Mock treatment (PX0.05). It is worth noting that similar results were observed using rAd encoding native IL-23 (data not shown), indicating that this mild antitumor effect was indeed attributable to IL-23 itself rather than to the mutated form of IL-23. Interestingly, the treatment with rAd/IL-23N220L caused temporal weight loss from about days 6 to 12 after initial treatment (data not shown), presumably due to a loss of appetite. Although the exact mechanism underlying weight loss after the IL-23 treatment is unclear, this adverse effect may be caused by IL-23-mediated tumor-necrosis factor (TNF)-a production which is known to directly suppress appetite. 19, 20 In this therapeutic setting, ELISPOT and intracellular cytokine staining assays were performed to determine whether the tumor-specific CD8 þ T-cell responses could be induced by rAd/IL-23N220L treatment in a therapeutic setting. The rAd/IL-23N220L-treated mice showed a significantly higher IFN-g ELISPOT activity specific for B16F10 and CT26 tumor cells than the rAd/Mockadministrated mice at day 8 following intratumoral injection of recombinant adenovirus (Figure 3a) . These activities were similar to those seen in rAd/IL-12N220L-treated mice. When the quantity of tumor-specific CD8 þ T cells was determined by flow cytometry analysis using double staining for CD8 and intracellular IFN-g, rAd/IL-23N220L-as well as rAd/IL-12N220L-treated mice generated significantly higher frequencies of tumorspecific CD8 þ T cells than did rAd/Mock-treated mice (Figure 3b) À DX5 þ NK cells were incubated with the supernatants derived from recombinant adenovirus-infected COS7 cells for 2 days, the NK cells stimulated with supernatants from rAd/IL-12N220L-, but not rAd/IL-23N220L-infected cells showed a significantly enhanced YAC-1 cell lysis. This result was also confirmed by using recombinant IL-23 and IL-12 proteins (rIL-23 and rIL-12; Figure 4a ). To further investigate whether IL-23 activates NK cells in the course of recombinant adenovirus treatment, we purified NK cells from the splenocytes of CT26 tumor-bearing mice at day 2 after intratumoral injection of each recombinant adenovirus or poly I:C as a positive control. It was previously reported that the NKcell-mediated killing activity was at its peak level at this point in time. 22 When the isolated NK cells were assayed for cytolytic activity against YAC-1 and CT26 cells, rAd/IL-12N220L and poly I:C treatments resulted in a significant cytolytic lysis against both targets (Figure 4b) . However, the rAd/IL-23N220L treatment absolutely did not affect the cytolytic activity of NK cells (Figure 4b 
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H-T Jin et al cells. 23 In a prophylactic setting, the co-injection of rAd/ IL-23N220L still showed potent protective antitumor effects against challenge of E.G7 tumor cells in beige mice, which is similar to that of rAd/IL-12N220L (Figure 5a ). In fact, there is no significant difference in rAd/IL-23N220L-mediated antitumor activity between wild-type mice ( Figure 1b) and beige mice, indicating that NK cells are dispensable for antitumor activity in a prophylactic setting. However, the potent therapeutic antitumor activity of rAd/IL-12N220L observed in wild-type mice was markedly impaired in the beige mice (Figure 5b ). These results indicate that NK cells play a critical role in the regression of established tumor in a therapeutic setting, which agrees well with the previous reports. 22, 24, 25 It is worth noting that IL-12 inhibits tumor growth better than IL-23 in beige mice, presumably due to other action mechanisms of IL-12 such as inhibition of angiogenesis and induction of nitric oxide production. 26 To confirm the role of NK cells in the regression of established tumor, we adoptively transferred the activated NK cells induced by poly I:C into the mice bearing CT26 or B16F10 tumors at 1 day after the intratumoral injection of rAd/IL-23N220L. As shown in Figure 6 , those mice that received either activated NK cells or intratumoral injection of rAd/IL-23N220L showed a slight retardation of tumor growth as compared with the control mice, which is statistically insignificant. In contrast, significant antitumor activity was observed through the co-treatment of activated NK cells and rAd/IL-23N220L in two different tumor models ( Figures  6a and b) , indicating a synergistic effect. Thus, the inability of IL-23 to activate NK cells may be one of the major reasons why IL-23 showed few antitumor effects compared to IL-12 in a therapeutic setting.
Discussion
In this study, we investigated the antitumor effects by adenovirus-mediated gene transfer of IL-23N220L in therapeutic as well as prophylactic settings and compared them with those of IL-12. In a prophylactic setting, co-injection of IL-23 with the surrogate tumor antigen (OVA) significantly enhanced antigen-specific CD8 
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could not stimulate NK cells in vitro and in vivo. On the contrary, IL-12 could activate both CD8 þ T and NK cells, leading to potent therapeutic antitumor effects. Interestingly, this therapeutic efficacy of IL-12 was significantly impaired in NK cell-defective beige mice. In addition, the adoptive transfer of activated NK cells with IL-23 treatment enhanced the therapeutic efficacy of IL-23, emphasizing the importance of NK cells in this therapeutic setting. Therefore, one of the reasons for the lack of significant therapeutic antitumor effect by IL-23 may be due to its intrinsic inability to activate NK cells. Besides the activation of CD8 þ T cells and NK cells, there are complex antitumor mechanism of IL-12, such as the activation of macrophages and NKT cells, the inhibition of angiogenesis and the induction of nitric oxide production. 5 In this context, we cannot exclude the possible involvement of other antitumor mechanisms in addition to NK cell activity for the differential antitumor effects of IL-23 in prophylactic and therapeutic models. It was previously reported that IL-23 receptor was expressed in human NK cell lines, 7 suggesting that NK cells could be responsive to IL-23. However, there may be a degree of difference in the expression pattern of the IL-23 receptor in human and mouse NK cells. Also, their receptor expression pattern could be heterogeneous depending on their functional status. [27] [28] [29] Alternatively, the inability of IL-23 to activate NK cells could be explained by the difference in a receptor-mediated signaltransduction cascade. In IL-23-mediated signal transduction, IL-23 stimulates a similar spectrum of Jak/Stat molecules to IL-12: Jak2, Tyk2, Stat1, Stat3, Stat4 and Stat5. 7 However, it was shown that IL-23 and IL-12 rAd/IL-12N220L Figure 3 Tumor-specific CD8 þ T-cell responses induced by intratumoral injection of recombinant adenovirus. At day 8 after recombinant adenovirus injection, the splenocytes were prepared from C57BL/6 and BALB/c mice bearing B16F10 and CT26 tumors, respectively. The number of tumor-specific interferon (IFN)-g-producing cells was determined by an ELISPOT assay. The data are presented as a mean ±s.e.m. of five mice. This result was reproduced in three independent experiments (a). At the same time, the percentage of tumor-specific IFN-gproducing cells among CD8 þ T cells was calculated using splenocytes from CT26-bearing BALB/c mice by fluorescence-activated cell sorting (FACS) analysis. The numbers in the upper-right quadrant indicate the percentage of IFN-g-secreting cells among the total CD8 þ T cells after stimulation with media or CT26 tumor cells. The representative result from three independent experiments with five mice per group is shown in (b).
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H-T Jin et al predominantly activate Stat3 and Stat4, respectively. 7, 30 Stat4 is essential for IL-12-mediated responses including perforin-mediated NK cell activity, 31, 32 whereas Stat3 may be involved in mediating more general types of signals such as those for cell growth and survival. 33, 34 It was recently reported that the expression of IL-23 was increased in a human tumor, and that the growth of the transplanted tumor was restricted in mice depleted for IL-23p19 or IL-23R. 10 The role of IL-23 in promoting tumor incidence and growth could be attributed to not only the increase of inflammation-mediated angiogenesis, but also the reduction of CD8 þ T-cell infiltration. 10 These findings partly explain why adenovirus-mediated gene transfers of IL-23 have little antitumor effects in a therapeutic setting. On the contrary, several reports demonstrated potent antitumor effects of IL-23 in genetically engineered tumor models. IL-23-overexpressing tumors showed the reduction of tumor growth and metastasis that are consistent with the stimulation of CD8 þ T-cell response. 9, 35, 36 This discrepancy may be caused by differences in the study design and tumors used, which could result in the different amount and duration of IL-23 expression.
Cancer immunoprevention has already been demonstrated in humans for tumors related to viral infection. For example, hepatitis B vaccination significantly reduces the risk of hepatocellular carcinoma, and papilloma virus vaccines are being tested to prevent cervical cancer. 37, 38 Recently, predictive oncology provides many instances in which the risk of cancer can be determined with sufficient accuracy, and immunological studies outline the probability of a specific tumor antigen being expressed by certain type of tumor. 39 Now, the challenge is to devise new preventive vaccines for human tumors not linked to viruses, such as breast, prostate and colorectal carcinomas. 1 It is therefore important to identify new cytokine adjuvants that can augment the immunogenicity and preventive effects of cancer vaccine. Earlier findings 
DX5
þ NK cells were isolated by MACS. The purified NK cells were incubated with the culture supernatants from recombinant adenovirusinfected cells, recombinant IL-12 protein (rIL-12) or recombinant IL-23 protein (rIL-23). After 48 h of incubation, their cytotoxicity was determined against 51 Cr-labeled YAC-I. These results were reproduced in three independent experiments (a). To measure NK cell activity in vivo, splenocytes were prepared from mice bearing CT26 tumor at day 2 after intratumoral injection of each recombinant adenovirus and from mice intraperitoneally given 150 mg of poly I:C. After isolating CD3 À
þ NK cells by MACS, the lytic activity of NK cells was analyzed against 51 Cr-labeled YAC-1 and CT26 target cells. The data are presented as a mean±s.e.m. from two independent experiments with four mice per group (b).
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reported that antitumor effects were completely lost by in vivo CD8
þ T-cell depletion in a prophylactic model, 40, 41 emphasizing the major role of long-lived memory CD8 þ T cells in preventing subsequent tumor challenge. We previously found that IL-23 induced long-lasting CD8 þ T-cell response to co-delivered antigens in a DNA vaccine. 13 Herein, we demonstrated that adenovirusmediated gene transfer of IL-23 could induce strong tumor antigen-specific CD8 þ T-cell response followed by the potent prophylactic antitumor effect. Collectively, we suggest that IL-23 as a genetic adjuvant could be useful for the development of prophylactic cancer vaccines.
Our results indicate that cancer vaccines may be more effective in prophylaxis than in treatment. We used OVA as a surrogate tumor antigen to clarify the relationship between antitumor efficacy and tumor-specific immunity. As the OVA antigen is not tolerized in the host such as viral or mutated protein, it would not be indicative of other tumor antigens to which the host has developed tolerance. However, this differential efficacy of the cancer vaccine in prophylaxis and therapy has been proven by several other studies evaluating the feasibility of a cancer vaccine with tolerized tumor antigens. [42] [43] [44] [45] [46] Novakovic et al. 44 found that the proportion of protected mice was 75-100% by vaccination of irradiated melanoma tumor cells with CpG ODN in a prophylactic setting whereas the rates of cured mice were only 11.1-21.1% in a therapeutic setting. Garcia-Hernandez Mde et al. 45 recently reported that prophylactic vaccination with a prostate antigen, six-transmembrane epithelial antigen of prostate, significantly delayed tumor growth and improved survival whereas therapeutic vaccination induced a modest delay in the growth of established prostate tumors. Moreover, in a HER-2/neu transgenic mouse model which closely mimics the natural history of human tumors, early vaccination produced a significantly delay in the onset of tumors, whereas late vaccination was completely devoid of an effect in comparison to untreated control mice. 42, 46 There are many reasons why vaccination is poorly effective as a tumor therapy. 1 One of them is the lag time of inducing tumor-specific adaptive immunity, leading to the generation of an immunosuppressive environment by the growing tumor in a therapeutic setting. 47 Thus, a rapid and robust innate immune response may also be required for successful immunotherapy for the established tumor. Particularly, NK cells may play a key role in therapeutic antitumor effects based on the following reasons: at first, the activated NK cells in the earliest stage of immune responses can directly kill tumor cells before the onset of tumor-specific CD8 þ T cells. 21, 48 In fact, IL-12-activated NK cells could respond with tumor killing as early as 48 h after treatment. 22 Second, NK cells are known to assist CD8 þ T lymphocyte activation, expansion and maturation to elicit tumor rejection, which is partially mediated by the interaction between NK cells and DCs. 49, 50 Finally, the activated NK cells can produce a wide array of inflammatory cytokines, including IFN-g, TNF-a, granulocyte monocyte colony-stimulating factor (GM-CSF), IL-2, IL-5 and IL-8, which may create a better stimulatory environment for tumor-specific CD8 þ T cells to eradicate established tumors. 51 To our knowledge, this is the first report showing that IL-23 can activate tumor-specific CD8 þ T cells but not NK cells, leading to a potent preventive but not therapeutic effect against cancer in adenovirus-mediated gene therapy. Therefore, our data suggest that different strategies should be used for prophylactic and therapeutic immunotherapy against cancer.
